Exact Sciences Corporation
EXAS
Rank in Stocks
#1149
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Share Price
$104.91
Last synced: 2026-03-23
Market Cap
$20.03B
Change (1 day)
0.00%
Change (1 year)
71.34%
Country
US
Trade Exact Sciences Corporation (EXAS)
Category
Healthcare
Earnings for Exact Sciences Corporation (EXAS)
Earnings in Dec 2025 TTM: $-203.89M
According to Exact Sciences Corporation latest financial reports the company's current earnings are $-203.89M. In 2024 the company made an earning of $-1.04B, a decrease compared to its 2023 earnings that were of $-201.75M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Exact Sciences Corporation from 2000 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-203.89M | -3.83% |
| 2025 | $-212.01M | -79.54% |
| 2024 | $-1.04B | 413.60% |
| 2023 | $-201.75M | -68.11% |
| 2022 | $-632.57M | -24.92% |
| 2021 | $-842.51M | 1.62% |
| 2020 | $-829.06M | 103.98% |
| 2019 | $-406.44M | 132.18% |
| 2018 | $-175.06M | 52.78% |
| 2017 | $-114.58M | -31.47% |
| 2016 | $-167.21M | 5.96% |
| 2015 | $-157.80M | 57.73% |
| 2014 | $-100.05M | 115.09% |
| 2013 | $-46.51M | -11.27% |
| 2012 | $-52.42M | 82.81% |
| 2011 | $-28.68M | 148.14% |
| 2010 | $-11.56M | 26.60% |
| 2009 | $-9.13M | -6.29% |
| 2008 | $-9.74M | -18.55% |
| 2007 | $-11.96M | -7.40% |
| 2006 | $-12.92M | -11.05% |
| 2005 | $-14.52M | -21.61% |
| 2004 | $-18.52M | -34.64% |
| 2003 | $-28.34M | -5.16% |
| 2002 | $-29.88M | -99.87% |
| 2001 | $-23.49B | 176,087.09% |
| 2000 | $-13.33M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $7.61B | -3,831.95% |
US
|
|
| $4.76B | -2,435.60% |
US
|
|
| $-252.70M | 23.94% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -913.19% |
US
|
